SLG 100
Alternative Names: SLG-100Latest Information Update: 15 May 2024
At a glance
- Originator SELAGINE
- Class Anti-inflammatories; Eye disorder therapies; Immunoglobulins
- Mechanism of Action Cytokine inhibitors; Inflammation mediator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry eyes
Most Recent Events
- 15 May 2024 SLG 100 licensed to Grifols worldwide (SELAGINE pipeline; May 2024)
- 15 May 2024 Grifols plans phase-IIb trial for Dry eyes (Opthalmic) (SELAGINE pipeline; May 2024)
- 06 May 2024 Preclinical trials in Dry eyes in USA (Ophthalmic) (SELAGINE pipeline; May 2024)